MANAGEMENT3

  • Mammalian target of rapamycin (mTOR) inhibitors can stabilize or slow decline in pulmonary function in patients who have progressive disease, with FEV1 <70%
  • Lung transplantation

See also

Patient Case Study 1

Test your knowledge

Take the test

bridging gaps in ILD education image

Bridging Educational Gaps in ILD

Learn more

Interstitial lung disease in systemic sclerosis with a focus on chest CT

Media Library

See Media